Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 5289
- Development stage
- Unknown
- Lead developer
- Sahlgrenska University Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus reuteri* (recently reclassified as *Limosilactobacillus reuteri*) is a Gram-positive, commensal bacterium widely used as a probiotic. This specific investigational product, studied at Sahlgrenska University Hospital, consists of a 1:1 ratio of two specific strains: DSM 17938 (a daughter strain of ATCC 55730) and ATCC PTA 5289. It is being evaluated for its ability to modulate the maternal and neonatal microbiome and reduce systemic inflammation when administered to pregnant women during the third trimester. The strains are known to produce reuterin, an antimicrobial compound, and modulate the host immune response through interaction with the intestinal and oral mucosa. The product is formulated in various oral delivery systems, including lozenges, chewing gum, and capsules, to assess microbiome transmission from mother to infant during birth.
- Brand names
- BioGaia Gastrus
- Other names
- L-Sahlgrenska University HospitalLimosilactobacillus reuteriL. reuteri
Beyond the preview
Go deeper on Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 5289.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 5289.